Evidence map›Paper›PMID 41103259›Full record

ArticleAnnals of medicine2025

Association of aspirin use alone with mortality and liver-related events in MASLD: a multi-institutional three-year study.

Chien-Hao Huang, Chun-Li Wang, Victor Chien-Chia Wu, Yi-Chung Hsieh, Chia-Ling Wu, Z-Fan Zeng, Yu-Tung Huang, Chao-Wei Hsu, Rong-Nan Chien, Shang-Hung Chang

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chien-Hao HuangDivision of Hepatology, Department of Gastroenterology and Hepatology, Chang-Gung Memorial Hospital, Linkou Medical Center, Linkou, Taiwan.ORCID 0000-0003-1689-3221
Chun-Li WangCollege of Medicine, Chang-Gung University, Taoyuan City, Taiwan.
Victor Chien-Chia WuCollege of Medicine, Chang-Gung University, Taoyuan City, Taiwan.
Yi-Chung HsiehDivision of Hepatology, Department of Gastroenterology and Hepatology, Chang-Gung Memorial Hospital, Linkou Medical Center, Linkou, Taiwan.
Chia-Ling WuDepartment of Medical Research and Development, Center for Big Data Analytics and Statistics, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan City, Taiwan.
Z-Fan ZengDivision of Hepatology, Department of Gastroenterology and Hepatology, Chang-Gung Memorial Hospital, Linkou Medical Center, Linkou, Taiwan.
Yu-Tung HuangDepartment of Medical Research and Development, Center for Big Data Analytics and Statistics, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan City, Taiwan.ORCID 0000-0003-3224-7238
Chao-Wei HsuDivision of Hepatology, Department of Gastroenterology and Hepatology, Chang-Gung Memorial Hospital, Linkou Medical Center, Linkou, Taiwan.
Rong-Nan ChienDivision of Hepatology, Department of Gastroenterology and Hepatology, Chang-Gung Memorial Hospital, Linkou Medical Center, Linkou, Taiwan.ORCID 0000-0001-7656-4695
Shang-Hung ChangCollege of Medicine, Chang-Gung University, Taoyuan City, Taiwan.ORCID 0000-0003-0462-2344

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as NAFLD, is increasing. While daily aspirin use has been associated with reduced hepatocellular carcinoma (HCC) risk in NAFLD, its impact on mortality and liver-related outcomes in MASLD remains unclear.

methodsThis retrospective, multi-institutional cohort study included 48,722 MASLD patients from 2008 to 2020, divided into aspirin users and non-users. Exclusion criteria included significant cardiac disease unrelated to aspirin, alcoholic liver disease, incomplete follow-up, and concomitant use of other antiplatelet therapies. Propensity score matching (PSM) was performed to balance baseline characteristics, including demographics, cirrhosis status, ALT levels, cardiovascular conditions, and concurrent medications.

resultsAfter PSM, 2003 patients were included in each cohort. Aspirin users had a mean duration of use of 4.59 ± 3.97 years, with 97% on a daily dose of 75-100 mg. Over three years, aspirin use was not significantly associated with reductions in overall mortality, liver-related events, liver-related mortality, or HCC incidence compared to non-users. However, a trend toward lower liver-related mortality and HCC incidence was observed without an increased risk of major bleeding.

conclusionIn this large cohort, daily aspirin use alone did not significantly reduce mortality or liver-related events in MASLD patients over three years. The observed trends may suggest potential long-term benefits, warranting further investigation into extended aspirin duration and combination strategies for MASLD management.

Indexed as

AspirinCarcinoma, HepatocellularLiver NeoplasmsNon-alcoholic Fatty Liver DiseasePlatelet Aggregation InhibitorsAgedFemaleHumansIncidenceMaleMiddle AgedPropensity ScoreRetrospective StudiesAspirinPlatelet Aggregation Inhibitorsall-cause mortalityantiplatelet therapyhepatocellular carcinoma (HCC)liver-related mortalitymajor bleeding eventsMetabolic dysfunction-associated steatotic liver disease (MASLD)non-alcoholic fatty liver disease (NAFLD)

Identifiers

PMID41103259
PMCPMC12536622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.